Olivera J. Finn - Publications

University of Pittsburgh, Pittsburgh, PA, United States 
Immunology, Oncology, Cell Biology

54/100 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Frontiers in Immunology. 10: 1401. PMID 31275327 DOI: 10.3389/fimmu.2019.01401  1
2017 Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 7: e1368604. PMID 29296519 DOI: 10.1080/2162402X.2017.1368604  0.4
2017 Cascio S, Faylo JL, Sciurba JC, Xue J, Ranganathan S, Lohmueller JJ, Beatty PL, Finn OJ. Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer. Oncotarget. 8: 105284-105298. PMID 29285251 DOI: 10.18632/oncotarget.22168  1
2016 Cascio S, Finn OJ. Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis. Biomolecules. 6. PMID 27754373 DOI: 10.3390/biom6040039  0.44
2016 Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, Innocenti GM, Cudic M, Ham JD, Cheung WC, Polakiewicz RD, Finn OJ. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Scientific Reports. 6: 31740. PMID 27545199 DOI: 10.1038/srep31740  0.76
2016 Beatty PL, van der Geest R, Hashash JG, Kimura T, Gutkin D, Brand RE, Finn OJ. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunology, Immunotherapy : Cii. PMID 27106024 DOI: 10.1007/s00262-016-1838-1  1
2016 Finn OJ, Beatty PL. Cancer immunoprevention. Current Opinion in Immunology. 39: 52-8. PMID 26799207 DOI: 10.1016/j.coi.2016.01.002  1
2015 Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A. Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study. Disease Markers. 2015: 179689. PMID 26693201 DOI: 10.1155/2015/179689  0.76
2015 Cascio S, Finn OJ. Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis. Cancers. 7: 342-52. PMID 25675408 DOI: 10.3390/cancers7010342  0.44
2014 Iheagwara UK, Beatty PL, Van PT, Ross TM, Minden JS, Finn OJ. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunology Research. 2: 263-73. PMID 24778322 DOI: 10.1158/2326-6066.CIR-13-0125  0.76
2014 Marvel DM, Finn OJ. Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10. Frontiers in Immunology. 5: 59. PMID 24596571 DOI: 10.3389/fimmu.2014.00059  0.56
2014 Farkas AM, Finn OJ. Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. Journal of Immunology (Baltimore, Md. : 1950). 192: 658-65. PMID 24337381 DOI: 10.4049/jimmunol.1301904  0.88
2013 Cascio S, Farkas AM, Hughey RP, Finn OJ. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration Oncotarget. 4: 1686-1697. PMID 24072600  0.76
2013 Beatty PL, Finn OJ. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Annals of the New York Academy of Sciences. 1284: 52-6. PMID 23651193 DOI: 10.1111/nyas.12108  1
2013 Farkas AM, Marvel DM, Finn OJ. Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. Journal of Immunology (Baltimore, Md. : 1950). 190: 3319-27. PMID 23420890 DOI: 10.4049/jimmunol.1203321  0.88
2013 Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prevention Research (Philadelphia, Pa.). 6: 18-26. PMID 23248097 DOI: 10.1158/1940-6207.CAPR-12-0275  0.76
2012 Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: S1-100. PMID 22977188 DOI: 10.1158/1078-0432.CCR-12-2891  0.76
2012 Beatty P, Ranganathan S, Finn OJ. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology. 1: 263-270. PMID 22737601 DOI: 10.4161/onci.18950  0.76
2012 Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA. Preventive immunization of aged and juvenile non-human primates to β-amyloid. Journal of Neuroinflammation. 9: 84. PMID 22554253 DOI: 10.1186/1742-2094-9-84  0.76
2011 Cascio S, Zhang L, Finn OJ. MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. The Journal of Biological Chemistry. 286: 42248-56. PMID 22021035 DOI: 10.1074/jbc.M111.297630  0.44
2011 Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8 + T cells European Journal of Immunology. 41: 3351-3360. PMID 21887788 DOI: 10.1002/eji.201141629  0.76
2011 Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunologic Research. 50: 261-8. PMID 21717081 DOI: 10.1007/s12026-011-8214-1  1
2010 Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology, Immunotherapy : Cii. 59: 1685-96. PMID 20652244 DOI: 10.1007/s00262-010-0895-0  0.76
2010 Ryan SO, Turner MS, Gariépy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Research. 70: 5788-96. PMID 20587526 DOI: 10.1158/0008-5472.CAN-09-4519  0.76
2010 Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF, Finn OJ. Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes & Control : Ccc. 21: 1193-201. PMID 20559706 DOI: 10.1007/s10552-010-9546-1  0.76
2010 Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1595-601. PMID 20501761 DOI: 10.1158/1055-9965.EPI-10-0068  0.76
2010 Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Seminars in Immunology. 22: 125-31. PMID 20403708 DOI: 10.1016/j.smim.2010.03.003  0.88
2010 Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer Cancer Prevention Research. 3: 438-446. PMID 20332301 DOI: 10.1158/1940-6207.CAPR-09-0194  0.76
2010 Kadayakkara DK, Beatty PL, Turner MS, Janjic JM, Ahrens ET, Finn OJ. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas. 39: 510-5. PMID 20084048 DOI: 10.1097/MPA.0b013e3181bd6501  0.76
2010 Furr AE, Ranganathan S, Finn OJ. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 13: 24-31. PMID 19025220 DOI: 10.2350/08-06-0479.1  0.4
2009 Finn OJ, Edwards RP. Human papillomavirus vaccine for cancer prevention. The New England Journal of Medicine. 361: 1899-901. PMID 19890134 DOI: 10.1056/NEJMe0907480  0.76
2009 Vella LA, Yu M, Phillips AB, Finn OJ. Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Annals of the New York Academy of Sciences. 1174: 68-73. PMID 19769738 DOI: 10.1111/j.1749-6632.2009.04941.x  0.76
2009 Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.CCR-09-0737  0.76
2009 Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 14010-5. PMID 19666607 DOI: 10.1073/pnas.0903225106  0.76
2009 Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice Biological Chemistry. 390: 611-618. PMID 19426130 DOI: 10.1515/BC.2009.070  0.76
2009 Silk AW, Schoen RE, Potter DM, Finn OJ. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Molecular Immunology. 47: 52-6. PMID 19217667 DOI: 10.1016/j.molimm.2008.12.025  0.76
2007 Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. Journal of Immunology (Baltimore, Md. : 1950). 179: 735-9. PMID 17617560  0.76
2007 Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncology (London, England). 3: 299-306. PMID 17547525 DOI: 10.2217/14796694.3.3.299  0.76
2007 Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. Journal of Immunology (Baltimore, Md. : 1950). 178: 2787-93. PMID 17312122  0.76
2007 Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 30-5. PMID 17220329 DOI: 10.1158/1055-9965.EPI-06-0688  0.76
2006 Alajez NM, Eghtesad S, Finn OJ. Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. Journal of Biomedicine & Biotechnology. 2006: 68091. PMID 16883054 DOI: 10.1155/JBB/2006/68091  0.76
2006 Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Research. 66: 6-9. PMID 16397206 DOI: 10.1158/0008-5472.CAN-05-3389  0.76
2005 Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treatment and Research. 123: 89-111. PMID 16211867  0.76
2005 Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. Journal of Immunology (Baltimore, Md. : 1950). 175: 1628-35. PMID 16034102  0.76
2005 Alajez NM, Schmielau J, Alter MD, Cascio M, Finn OJ. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 105: 4583-9. PMID 15746083 DOI: 10.1182/blood-2004-10-3848  0.76
2005 Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1521-6. PMID 15746055 DOI: 10.1158/1078-0432.CCR-04-0538  0.76
2004 Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Disease. 20: 73-9. PMID 15687709  0.76
2004 Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Advances in Immunology. 82: 249-93. PMID 14975259 DOI: 10.1016/S0065-2776(04)82006-6  0.76
2002 Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Hanisch FG, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. The Journal of Experimental Medicine. 196: 1435-46. PMID 12461079  0.76
2002 Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clinical & Experimental Metastasis. 19: 339-45. PMID 12090474  0.52
2001 Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. The Journal of Experimental Medicine. 194: 1313-23. PMID 11696596 DOI: 10.1084/jem.194.9.1313  0.76
2001 Kao H, Amoscato AA, Ciborowski P, Finn OJ. A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 773s-780s. PMID 11300472  0.52
2000 Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 165: 3730-41. PMID 11034378  0.76
1998 Barratt-Boyes SM, Kao H, Finn OJ. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 142-8. PMID 9551366  0.52
Low-probability matches
2008 Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy. 6: 955-964. PMID 19129927  0.28
2008 Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Critical Reviews in Oncology/Hematology. 67: 93-102. PMID 18400507 DOI: 10.1016/j.critrevonc.2008.02.010  0.28
2007 Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. International Archives of Allergy and Immunology. 142: 179-89. PMID 17106205 DOI: 10.1159/000097020  0.28
2018 Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: Immune modulation taking the stage. Biochimica Et Biophysica Acta. PMID 29391185 DOI: 10.1016/j.bbcan.2017.12.002  0.2
2003 Turner MS, McKolanis JR, Ramanathan RK, Whitcomb DC, Finn OJ. Mucins in gastrointestinal cancers. Cancer Chemotherapy and Biological Response Modifiers. 21: 259-74. PMID 15338749  0.2
2013 Mandapathil M, Visus C, Finn OJ, Lang S, Whiteside TL. Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology. 2: e25514. PMID 24073385 DOI: 10.4161/onci.25514  0.16
2013 Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opinion On Biological Therapy. 13: 35-49. PMID 22998452 DOI: 10.1517/14712598.2012.725719  0.12
2009 Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Molecular Immunology. 47: 131-40. PMID 19007994 DOI: 10.1016/j.molimm.2008.09.032  0.12
2013 Zhang L, Vlad A, Milcarek C, Finn OJ. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunology, Immunotherapy : Cii. 62: 423-35. PMID 22941036 DOI: 10.1007/s00262-012-1325-2  0.04
2018 Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 200: 385-391. PMID 29311379 DOI: 10.4049/jimmunol.1701302  0.01
2017 Finn OJ. The dawn of vaccines for cancer prevention. Nature Reviews. Immunology. PMID 29279613 DOI: 10.1038/nri.2017.140  0.01
2017 Finn OJ, Rammensee HG. Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. Cold Spring Harbor Perspectives in Biology. PMID 29254980 DOI: 10.1101/cshperspect.a028829  0.01
2017 Finn OJ. Human Tumor Antigens Yesterday, Today, and Tomorrow. Cancer Immunology Research. 5: 347-354. PMID 28465452 DOI: 10.1158/2326-6066.CIR-17-0112  0.01
2017 Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 77: 1510-1541. PMID 28373404 DOI: 10.1158/0008-5472.CAN-16-2346  0.01
2017 Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacology & Therapeutics. PMID 28322974 DOI: 10.1016/j.pharmthera.2017.03.008  0.01
2016 Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee S, Dekaban GA, Fink C, Foster P, et al. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer. Cancer Immunology Research. PMID 27604597 DOI: 10.1158/2326-6066.CIR-15-0189  0.01
2015 Finn OJ, Khleif SN, Herberman RB. The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them. Cancer Prevention Research (Philadelphia, Pa.). 8: 1011-6. PMID 26353948 DOI: 10.1158/1940-6207.CAPR-15-0234  0.01
2014 Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunology Research. 2: 708-13. PMID 25092812 DOI: 10.1158/2326-6066.CIR-14-0110  0.01
2013 Reichenbach DK, Finn OJ. Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2: e23429. PMID 23802084 DOI: 10.4161/onci.23429  0.01
2013 Finn OJ, Schuler G. Introduction to The Renaissance of Cancer Immunotherapy. Annals of the New York Academy of Sciences. 1284: v-vii. PMID 23651200 DOI: 10.1111/nyas.12153  0.01
2012 Finn OJ. Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. Experimental and Molecular Pathology. 93: 315-8. PMID 23099314 DOI: 10.1016/j.yexmp.2012.10.013  0.01
2011 Finn OJ. Preface: Happy 10th anniversary! Immunologic Research. 50: 103-4. PMID 21717062 DOI: 10.1007/s12026-011-8233-y  0.01
2011 Melief CJ, Finn OJ. Cancer immunology. Current Opinion in Immunology. 23: 234-6. PMID 21292460 DOI: 10.1016/j.coi.2011.01.003  0.01
2011 Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Current Opinion in Immunology. 23: 265-71. PMID 21277761 DOI: 10.1016/j.coi.2011.01.002  0.01
2010 Guinipero T, Finn OJ. Cancer vaccines: emphasis on pediatric cancers. Current Pharmaceutical Design. 16: 292-9. PMID 20109138  0.01
2009 Chen X, Gao W, Gambotto A, Finn OJ. Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 977-87. PMID 19023569 DOI: 10.1007/s00262-008-0624-0  0.01
2008 Finn OJ. Immunological weapons acquired early in life win battles with cancer late in life. Journal of Immunology (Baltimore, Md. : 1950). 181: 1589-92. PMID 18641292  0.01
2008 Finn OJ. Cancer immunology. The New England Journal of Medicine. 358: 2704-15. PMID 18565863 DOI: 10.1056/NEJMra072739  0.01
2008 Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Research. 68: 2419-26. PMID 18381450 DOI: 10.1158/0008-5472.CAN-07-2249  0.01
2008 Finn OJ. Tumor immunology top 10 list. Immunological Reviews. 222: 5-8. PMID 18363991 DOI: 10.1111/j.1600-065X.2008.00623.x  0.01
2007 Finn OJ. Human tumor immunology at the molecular divide. Journal of Immunology (Baltimore, Md. : 1950). 178: 2615-6. PMID 17312098  0.01
2006 Finn OJ. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunologic Research. 36: 73-82. PMID 17337768 DOI: 10.1385/IR:36:1:73  0.01
2006 Finn OJ, Salter RD. Immunology in Pittsburgh. Immunologic Research. 36: 1-2. PMID 17337760 DOI: 10.1385/IR:36:1:1  0.01
2006 Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J, Palucka AK. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Research : Bcr. 8: R65. PMID 17129372 DOI: 10.1186/bcr1621  0.01
2006 Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunology, Immunotherapy : Cii. 55: 119-30. PMID 16032397 DOI: 10.1007/s00262-005-0008-7  0.01
2005 Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Annals of the New York Academy of Sciences. 1062: 29-40. PMID 16461786 DOI: 10.1196/annals.1358.005  0.01
2005 Finn OJ. Immune response as a biomarker for cancer detection and a lot more. The New England Journal of Medicine. 353: 1288-90. PMID 16177255 DOI: 10.1056/NEJMe058157  0.01
2005 Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1125-31. PMID 15894662 DOI: 10.1158/1055-9965.EPI-05-0035  0.01
2005 Finn OJ. Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004. Cancer Immunology, Immunotherapy : Cii. 54: 287-9. PMID 15517257 DOI: 10.1007/s00262-004-0618-5  0.01
2005 Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 54: 254-64. PMID 15372205 DOI: 10.1007/s00262-004-0581-1  0.01
2004 Finn OJ. Tumor immunology at the service of cancer immunotherapy. Current Opinion in Immunology. 16: 127-9. PMID 15023402 DOI: 10.1016/j.coi.2004.02.006  0.01
2003 Finn OJ. Premalignant lesions as targets for cancer vaccines. The Journal of Experimental Medicine. 198: 1623-6. PMID 14638849 DOI: 10.1084/jem.20031787  0.01
2003 Finn OJ. Cancer vaccines: between the idea and the reality. Nature Reviews. Immunology. 3: 630-41. PMID 12974478 DOI: 10.1038/nri1150  0.01
2003 Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology. 108: 32-41. PMID 12519300  0.01
2002 Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Molecular Immunology. 38: 981-7. PMID 12009577  0.01
2002 Finn OJ, Forni G. Prophylactic cancer vaccines. Current Opinion in Immunology. 14: 172-7. PMID 11869888  0.01
Hide low-probability matches.